Abstract | BACKGROUND: METHODS: Between June 1994 and June 2000, 15 patients with AL amyloidosis-associated ESRD were treated with intravenous melphalan (70 to 200 mg/m2) and autologous peripheral blood stem cell transplantation. Clinical and laboratory data were prospectively collected prior to treatment, during the peritransplant period, and at 3 months, 12 months, and annually thereafter. Treatment outcomes and toxicities were compared with 180 non- ESRD patients treated during the study period. RESULTS: Eight of 15 patients (53%) had a hematologic complete response following treatment. Two patients (13%) died during the peritransplant period. Transfusion requirements were greater and there was a trend toward increased severity of mucositis in the ESRD patients compared with the non- ESRD patients. Median survival for the ESRD patients with a hematologic complete response was 4.5 years. Five patients with hematologic complete response have either undergone or are awaiting renal transplantation. CONCLUSION:
|
Authors | Liam F Casserly, Amit Fadia, Vaishali Sanchorawala, David C Seldin, Daniel G Wright, Martha Skinner, Laura M Dember |
Journal | Kidney international
(Kidney Int)
Vol. 63
Issue 3
Pg. 1051-7
(Mar 2003)
ISSN: 0085-2538 [Print] United States |
PMID | 12631087
(Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antineoplastic Agents, Alkylating
- Melphalan
|
Topics |
- Adult
- Aged
- Amyloidosis
(complications, drug therapy, mortality)
- Antineoplastic Agents, Alkylating
(administration & dosage, adverse effects)
- Female
- Humans
- Injections, Intravenous
- Kidney Failure, Chronic
(drug therapy, etiology, mortality)
- Male
- Melphalan
(administration & dosage, adverse effects)
- Middle Aged
- Prospective Studies
- Remission Induction
- Stem Cell Transplantation
- Survival Analysis
- Transplantation, Autologous
|